<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
</table>
| Tetanus Diphtheria       | Td Adsorbed                 | Td      | All health care students and students in other high-risk occupational programs.                                                               | If no documented history of primary series:  
  - Complete a primary series of 3 doses [day 0, 4 to 8 weeks (28 to 56 days), 6 to 12 months after second dose]  
  <br>Note: A single dose of dTap should be given to adults as part of a primary series of tetanus/diphtheria-containing vaccine. Any remaining doses in the primary series should be given using Td vaccine ensuring the appropriate spacing.  
If documentation of primary series:  
  - Reinforcing dose of tetanus/diphtheria vaccine every 10 years.  
  <br>Note: A single dose of dTap as an adult is recommended as one of the reinforcing doses if not already received. |
| Pertussis¹               | Adacel®¹, Boostrix®¹         | dTap¹   | All health care students who have not previously received an adult dose of an acellular pertussis containing vaccine.                       | If no documented history of a dose of acellular pertussis vaccine as an adult:  
  - 1 dose of dTap regardless of the interval since the last dose of Td  
  Reinforcing doses are not routinely required.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Measles                  | MMR®II, Priorix®³           | MMR³    | All post-secondary health care students without documentation of 2 valid doses of measles-containing vaccine or without documented laboratory confirmed measles disease or serological evidence of measles immunity (measles IgG positive)³. | All post-secondary health care students  
  - 2 doses of measles-containing vaccine after 12 months of age  
  - Follow recommended minimum intervals for the specific vaccine.                                                                                                                                                                                                                                                                                                                                                                                                          |

¹ Pertussis – provided as combined diphtheria, tetanus, acellular pertussis vaccine  
² MMR - provided as combined measles, mumps rubella vaccine  
³ In general, serological testing to determine immunity to measles, mumps or rubella is not necessary or recommended and should not routinely be done for those who lack documentation of previous immunization.
<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>All other post secondary students:</td>
<td>All other post secondary students born in 1970 or later:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• <strong>born in 1970 or later</strong> without documentation of 2 valid doses of measles-containing vaccine or without documented laboratory confirmed measles disease or serological evidence of measles immunity (measles IgG positive)</td>
<td>• 2 doses of measles-containing vaccine after 12 months of age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• <strong>born prior to 1970</strong> 1 valid dose of measles-containing vaccine or without documented laboratory confirmed measles disease or serological evidence of immunity (measles IgG positive)</td>
<td>All other post secondary students born prior to 1970:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 1 dose of measles-containing vaccine after 12 months of age</td>
</tr>
<tr>
<td>Mumps</td>
<td>MMR®II&lt;sup&gt;3&lt;/sup&gt;</td>
<td>MMR&lt;sup&gt;3&lt;/sup&gt;</td>
<td>All post-secondary <strong>health care students</strong> without documentation of 2 valid doses of mumps-containing vaccine or without documented laboratory confirmed mumps disease&lt;sup&gt;4&lt;/sup&gt;.</td>
<td>All post-secondary <strong>health care students</strong></td>
</tr>
<tr>
<td></td>
<td>Priorix®&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
<td>All other post secondary students:</td>
<td>• 2 doses of mumps-containing vaccine after 12 months of age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• <strong>born in 1970 or later</strong> without documentation of 2 valid doses of mumps-containing vaccine or without documented laboratory confirmed mumps disease&lt;sup&gt;4&lt;/sup&gt;. (Mumps IgG serology is not an acceptable indicator of immunity).</td>
<td>○ Follow recommended minimum intervals for the specific vaccine.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• <strong>born prior to 1970</strong> 1 valid dose of mumps-containing vaccine or without documented laboratory confirmed mumps disease&lt;sup&gt;4&lt;/sup&gt; (Mumps IgG serology is not an acceptable indicator of immunity).</td>
<td>All other post secondary students <strong>born in 1970 or later</strong>:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 2 doses of mumps-containing vaccine after 12 months of age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All other post secondary students <strong>born prior to 1970</strong>:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 1 dose of mumps-containing vaccine after 12 months of age</td>
</tr>
<tr>
<td>Rubella</td>
<td>MMR®II&lt;sup&gt;3&lt;/sup&gt;</td>
<td>MMR&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Legislated under the Alberta Public Health Act, Communicable Diseases Regulation:</td>
<td>1 dose of rubella-containing vaccine after 12 months of age.</td>
</tr>
<tr>
<td></td>
<td>Priorix®&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
<td>• Students without documentation of at least one dose of rubella-containing vaccine or serological evidence of immunity (rubella IgG positive) who may have</td>
<td></td>
</tr>
<tr>
<td>Disease</td>
<td>Vaccine(s)</td>
<td>Acronym</td>
<td>Indication</td>
<td>Recommended Doses</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Hepatitis B  | Engerix®-B                         | HBV     | Eligibility for hepatitis B vaccine for health care students should be based on an assessment of the students reasonably anticipated risk of: | Primary series standard schedule is:  
• 3 doses spaced at 0, 1 and 6 months. The minimum acceptable intervals are 0, 1, and 4 months with:  
  o 1 month (28 days) between the first and second dose,  
  and  
  o At least 2 months (56 days) between the second and third dose,  
  and  
  o At least 4 months between the first and third dose.  
An alternative adolescent schedule of 2 doses of 1.0 mL administered on day 0 and 6 months later is also acceptable.  
Students who have received combined hepatitis A and B vaccine or hepatitis B vaccine using an accelerated schedule should be assessed using the minimum intervals outlined in the specific product monograph.  
Students who have lab confirmation of positive anti-HBs but without documentation of a complete hepatitis B vaccine series should be offered hepatitis B vaccine to complete the series to ensure long term immunity |
|              | Recombivax HB®                     |         | face to face contact with patients in health care facilities.⁴               |                                                                                 |
|              |                                   |         | See: Hepatitis B Risk Assessment.                                            |                                                                                 |

**Pre-immunization serology:**  
Pre-immunization serology for previous hepatitis B infection is **not indicated for all health care students**; it is indicated for the following **high-risk populations with a high probability of past infection** regardless of their immunization status:  
• Health care students from a hepatitis B endemic country  
• Health care students who have received repeated blood transfusions or blood product  
• Health care students who have a history of dialysis  
• Health care students who indicate lifestyle risks for infection

**Post-immunization serology:**  
All health care students who qualify for hepatitis B immunization:  
• 1 to 6 months after completion of series  
• If post immunization serology was not done within the recommended interval following immunization it should be done at time of assessment
<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
</table>
|         |            |         | Once a positive antibody result is recorded no further serology required | **Note:** The following are serological markers of laboratory evidence of immunity or disease:  
   - Positive anti-HBs, or  
   - Positive anti-HBc and/or  
   - HBsAg positive/reactive  
Refer to the following link for more detailed information on interpretation of hepatitis B serological tests.  
[https://open.alberta.ca/dataset/6d06b3c6-22d6-440f-85bb-a65c5e027d55/resource/1e0a546d-e019-4476-ae9b-466262bbcca0/download/guidelines-hepatitis-b-acute-case-2011.pdf](https://open.alberta.ca/dataset/6d06b3c6-22d6-440f-85bb-a65c5e027d55/resource/1e0a546d-e019-4476-ae9b-466262bbcca0/download/guidelines-hepatitis-b-acute-case-2011.pdf)  
**See:** Hepatitis B Virus Infection – High Endemic Geographic Areas.  
**See:** Hepatitis B Vaccine Recommendations Algorithm for Individuals Not at Risk of Past Infection.  
**See:** Hepatitis B Vaccine Recommendations Algorithm for Individuals at High-Risk of Past Infection. |
| Varicella | Varilrix™ Varivax® III | Vz | Students with none of the following:  
   - Documented history of 2 valid doses of varicella-containing vaccine; or  
   - Laboratory evidence of immunity; or  
   - Physician diagnosed shingles disease; or  
   - Self-reported history or physician diagnosed varicella disease in Canada prior to a routine immunization program:  
     o In Alberta, prior to January 2001.  
     o For start dates of other Canadian jurisdictions see the NACI Varicella Proof of Immunity - 2015 Update |  
   - 2 doses of varicella vaccine with a minimum interval of 3 months between doses.  
   - While Zostavax® vaccine is not indicated for and should not be used for prevention of varicella disease, it can be considered a valid first does in a 2-dose varicella vaccine series. (Shingrix doses cannot be counted in a varicella vaccine series).  
   - Individuals who received their first dose of varicella-containing vaccine and at any point subsequently developed laboratory confirmed vaccine modified varicella disease do not require a second dose of |
<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td><strong>Note:</strong> Annual influenza vaccine(s) may vary from year to year as determined and provided by AH</td>
<td>FLU</td>
<td>All students.</td>
<td>1 dose annually.</td>
</tr>
<tr>
<td>Polio</td>
<td>Imovax® Polio</td>
<td>IPV \ OPV(^4)</td>
<td>Due to the low risk of exposure to polio in Alberta and Canada for post-secondary student placements, post-secondary institutions are not expected to assess healthcare students for polio immunization. Once these students enter the workforce they will be assessed by Workplace Health and Safety staff for polio risk based on exposure at the clinical site where they will be employed and offered appropriate vaccine at that time.</td>
<td></td>
</tr>
</tbody>
</table>
| Meningococcal B | Bexsero® | Men-B | Research, industrial and clinical laboratory personnel routinely exposed to *N. meningitidis*. Includes those workers only involved in conducting subculture identification, susceptibility testing, serological and/or molecular characterization and deep freeze for storage. Laboratory workers who do only initial specimen plants are not eligible. | Eligible laboratory workers:  
- 2 doses with minimum 1 month between doses.  
The need for a reinforcing dose has not been established. | |
| Meningococcal (Neisseria meningitidis) | Menactra™  
Menveo™ | MenC-ACYW | Health care students (i.e., laboratory students) who are routinely exposed to *Neisseria meningitidis* through subculture identification, susceptibility testing, serological and or molecular characterization.  
- Meningococcal conjugate quadrivalent A, C, Y, W135 vaccine to be provided to eligible health care students who received a dose of meningococcal polysaccharide quadrivalent A, C, Y, W135 in the past and it has been 5 years since this dose. | All eligible students:  
- 1 dose of meningococcal conjugate quadrivalent A, C, Y, W135 vaccine.  
Though there is no data currently on the use of meningococcal conjugate quadrivalent vaccine in individuals 56 years of age and older; AH recommends this vaccine be used off license with the expectation of similar increased immune response and local reaction rates compared to meningococcal polysaccharide vaccine. | |
| Typhoid (Salmonella Typhi) | Typherix™  
Typhim Vi® | TYVI | Health care students (i.e., laboratory students) who regularly manipulate *Salmonella Typhi*. | Eligible health care students:  
- 1 primary dose. | |

\(^4\) OPV – oral polio vaccine (Sabin®) no longer available in Canada
<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
</table>
| Tuberculosis (Mycobacterium tuberculosis) | Tubersol® | PPD | The purpose of baseline tuberculin skin test (TST) for health care students on enrolment is to establish baseline\(^5\) Mycobacterium tuberculosis (TB) infection status in those individuals at risk for potential occupational exposure to an infectious case. The TST is recommended for health care students on enrolment (except those with a history of active TB disease or a history of a prior positive TST) as follows:  
- Those with undocumented\(^6\) prior TST results  
- Those with documentation of prior negative TST unless there has been a baseline TST within the past year (with no history of known exposure)  
- Those without history of prior TST (i.e., do not recall having received a TST before)  
See Tuberculin biological page, Scheduling Section and Health Care Workers for specific criteria. | Single baseline TST, unless there is a history of active TB disease or documentation of a previous positive TST\(^7\).  
- The TST must be read 48-72 hours later by a qualified provider, not self-read\(^8\).  
A baseline 2-step TST is only indicated for any health care students in special circumstances (see Tuberculin biological page, Scheduling Section and Health Care Workers for specific criteria). |
| Rabies | Imovax®Rabies RabAvert® | RAB | Students in programs related to animal health (including research), equine science and wildlife | If no history of a primary series:  
- Complete a pre-exposure intradermal\(^9\) (ID) series of 3 doses spaced at day 0, day 7, day 21 or 28.  
Post-immunization:  
- Rabies antibody titre determination is |

---

\(^5\) Health care students who may be working in health care facilities either during their training or on completion of their program should receive a baseline TST. Students in dental programs would not be included routinely as an eligible group for baseline TST unless they are working with high-risk individuals or in high-risk settings.  

\(^6\) Individuals who give a history of blistering TST reaction should not receive a TST. Individuals with history of undocumented positive TST reaction (other than blistering) can receive a TST; if these individuals decline the baseline TST they do require a baseline chest X-ray within the past 6 months through their family physician.  

\(^7\) Students with a history of active TB or positive TST should have a chest X-ray through their family physician.  

\(^8\) Self-reading of TST is not an acceptable practice, and should not be allowed under any circumstances.  

\(^9\) The ID route should not be used for students who are immune compromised, taking steroids or on chloroquine.
<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine(s)</th>
<th>Acronym</th>
<th>Indication</th>
<th>Recommended Doses</th>
</tr>
</thead>
</table>

- recommended 2 weeks after the third dose to ensure an acceptable level of protection has been achieved.
- Rabies antibody titre determination is recommended every 2 years to determine immunity for students at continued risk of rabies exposure;
- Rabies antibody titre determination is recommended every 6 months to determine immunity for student research lab workers working with live rabies virus at risk of inapparent exposure.

**Reinforcing dose:** Rabies antibody titre determination should be done first and a reinforcing dose given only if level is below that recommended for protection.

Post-exposure prophylaxis: Consult public health for specific information.